(Q36734781)

16 August 2017

1 reference

MDMA

0 references

title

The psychotherapeutic potential of MDMA (3,4-methylenedioxymethamphetamine): an evidence-based review (English)

1 reference

16 August 2017

Parrott AC

1

1 reference

16 August 2017

publication date

13 February 2007

1 reference

16 August 2017

1 reference

16 August 2017

volume

191

1 reference

16 August 2017

issue

2

1 reference

16 August 2017

page(s)

181-193

1 reference

A Clinical Plan for MDMA (Ecstasy) in the Treatment of Posttraumatic Stress Disorder (PTSD): Partnering with the FDA

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00213-007-0703-5

The psychological and physiological effects of MDMA on normal volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-007-0703-5

Subjective reports of the effects of MDMA in a clinical setting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-007-0703-5

A method of conducting therapeutic sessions with MDMA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-007-0703-5

A clinical crossroads for MDMA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-007-0703-5

Hallucinogenic drugs and plants in psychotherapy and shamanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-007-0703-5

Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-007-0703-5

Psychedelic and entactogenic drugs in the treatment of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-007-0703-5

The background and chemistry of MDMA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-007-0703-5

Vasopressin and oxytocin secretion in response to the consumption of ecstasy in a clubbing population.

21 January 2018

1 reference

12 December 2020

Psychobiological problems in heavy 'ecstasy' (MDMA) polydrug users

1 reference

12 December 2020

Ecstasy/MDMA attributed problems reported by novice, moderate and heavy recreational users.

1 reference

12 December 2020

(+/-)3,4-Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: studies in animals

1 reference

12 December 2020

Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance

1 reference

12 December 2020

When acute-stage psychosis and substance use co-occur: differentiating substance-induced and primary psychotic disorders

1 reference

12 December 2020

Symptoms of anxiety and depression in childhood and use of MDMA: prospective, population based study

1 reference

12 December 2020

A review of acute effects of 3,4-methylenedioxymethamphetamine in healthy volunteers

1 reference

12 December 2020

(+/-)3,4-Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: clinical studies

1 reference

12 December 2020

Can drugs be used to enhance the psychotherapeutic process?

1 reference

12 December 2020

The content of ecstasy tablets: implications for the study of their long-term effects.

1 reference

12 December 2020

Recreational ecstasy/MDMA and other drug users from the UK and Italy: psychiatric symptoms and psychobiological problems

1 reference

12 December 2020

Causes and consequences of methamphetamine and MDMA toxicity

1 reference

12 December 2020

Can physiologic assessment and side effects tease out differences in PTSD trials? A double-blind comparison of citalopram, sertraline, and placebo

1 reference

12 December 2020

Ecstasy versus alcohol: Tolstoy and the variations of unhappiness.

1 reference

12 December 2020

Mood and cognitive effects of +/-3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'): week-end 'high' followed by mid-week low.

1 reference

12 December 2020

Psychedelic drugs: the ups and downs of ecstasy

1 reference

12 December 2020

The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy").

1 reference

12 December 2020

Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") and its congeners

1 reference

12 December 2020

Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective

1 reference

12 December 2020

Recreational Ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity

1 reference

12 December 2020

3,4-Methylenedioxymethamphetamine (MDMA) modulates cortical and limbic brain activity as measured by [H(2)(15)O]-PET in healthy humans

1 reference

12 December 2020

Former chronic methylenedioxymethamphetamine (MDMA or ecstasy) users report mild depressive symptoms

1 reference

12 December 2020

Drug-related schizophrenic syndromes.

1 reference

12 December 2020

Is ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, their dosage levels, and the changing perceptions of purity

1 reference

12 December 2020

Club drugs: MDMA, gamma-hydroxybutyrate (GHB), Rohypnol, and ketamine

1 reference

12 December 2020

Hallucinogens: An update

1 reference

12 December 2020

Empathy and aggression: two faces of ecstasy? A study of interpretative cognitive bias and mood change in ecstasy users

1 reference

12 December 2020

MDMA (3,4-Methylenedioxymethamphetamine) or ecstasy: the neuropsychobiological implications of taking it at dances and raves

1 reference

12 December 2020

Neurotoxicity of MDMA (ecstasy): the limitations of scaling from animals to humans.

1 reference

12 December 2020

Alcohol, ecstasy, Aldous Huxley's 'soma'.

1 reference

12 December 2020

Phenomenology and sequelae of 3,4-methylenedioxymethamphetamine use

1 reference

12 December 2020

Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research

1 reference

12 December 2020

Potential human neurotoxicity of MDMA ('Ecstasy'): subjective self-reports, evidence from an Italian drug addiction centre and clinical case studies

1 reference

12 December 2020

Experimentally induced aggressive behavior in subjects with 3,4-methylenedioxy-methamphetamine ("Ecstasy") use history: psychobiological correlates

1 reference

12 December 2020

Gender differences in the subjective effects of MDMA.

1 reference

12 December 2020

The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine ('Ecstasy') in healthy volunteers.

1 reference

12 December 2020

Decreased pain tolerance and mood in recreational users of MDMA.

1 reference

12 December 2020

Evidence for a role of energy dysregulation in the MDMA-induced depletion of brain 5-HT.

1 reference

12 December 2020

Remission in post-traumatic stress disorder (PTSD): effects of sertraline as assessed by the Davidson Trauma Scale, Clinical Global Impressions and the Clinician-Administered PTSD scale

1 reference

12 December 2020

Psychiatric disorders in Ecstasy (MDMA) users: a literature review focusing on personal predisposition and drug history

1 reference

12 December 2020

Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function

1 reference

12 December 2020

Impulsivity, risk taking and recreational 'ecstasy' (MDMA) use.

1 reference

12 December 2020

Neuroimaging findings with MDMA/ecstasy: technical aspects, conceptual issues and future prospects

1 reference

12 December 2020

Increased intensity of Ecstasy and polydrug usage in the more experienced recreational Ecstasy/MDMA users: a WWW study

1 reference

12 December 2020

Reversibility of ecstasy-induced reduction in serotonin transporter availability in polydrug ecstasy users.

1 reference

12 December 2020

Psychological and cardiovascular effects and short-term sequelae of MDMA ("ecstasy") in MDMA-naïve healthy volunteers

1 reference

12 December 2020

MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress

1 reference

12 December 2020

3,4-Methylenedioxy analogues of amphetamine: defining the risks to humans.

1 reference

12 December 2020

Psychobiologic effects of 3,4-methylenedioxymethamphetamine in humans: methodological considerations and preliminary observations

1 reference

12 December 2020

Differential experiences of the psychobiological sequelae of ecstasy use: quantitative and qualitative data from an internet study

1 reference

12 December 2020

A review of the acute subjective effects of MDMA/ecstasy

1 reference

12 December 2020

1 reference

12 December 2020

10.1007/S00213-007-0703-5

Identifiers

DOI

1 reference

16 August 2017

1 reference